Relmada's Phase III Timeline Could Redefine Its Investment Thesis

Relmada Therapeutics Inc. (RLMD) reports second-quarter 2026 earnings after market close on August 6, 2026, with analysts expecting a loss of $-0.21 per share. The central question for investors is whether the clinical-stage biotechnology company can demonstrate progress in narrowing losses as it advances its pipeline, particularly after four consecutive quarters of disappointing results. With the stock trading at $5.44 and analysts maintaining a bullish stance despite recent execution challenges, this report will test whether management can restore confidence in its development trajectory.

Part 1: Earnings Preview

Relmada Therapeutics operates as a clinical-stage biotechnology company focused on developing novel therapies, including REL-1017 for major depressive disorder and other neuropsychiatric conditions, as well as oncology candidates. The company's pipeline represents a high-risk, high-reward opportunity for investors betting on successful clinical development and regulatory approval.

Relmada is scheduled to report Q2 2026 earnings after market close on August 6, 2026, with the consensus estimate calling for a loss of $-0.21 per share from 2 analysts. The company most recently reported Q1 2026 results on May 12, 2026, posting a loss of $-0.22 per share. Comparing to the same quarter last year, the Q2 2026 estimate of $-0.21 represents a 30.00% improvement versus the $-0.30 loss reported in Q2 2025, suggesting analysts expect meaningful progress in cost management or development milestones.

Three key themes define this earnings story:

Clinical Pipeline Progress: Investors will scrutinize any updates on REL-1017's development path and the status of oncology programs including NDV-01. With the company's valuation heavily dependent on successful clinical outcomes, any advancement or setback in trial timelines will significantly impact sentiment.

Cash Runway and Burn Rate: As a pre-revenue biotech, Relmada's quarterly cash consumption and remaining runway are critical metrics. Analysts will focus on whether the company can extend its operational timeline without dilutive financing, particularly given the improved loss estimates suggesting better capital efficiency.

Regulatory Strategy and Timeline: Following recent disappointments, management's communication around regulatory pathways and expected approval timelines will be crucial. Investors need clarity on when the company might transition from cash-burning development to potential commercialization.

Analyst commentary ahead of the release reflects cautious optimism, with 6 of 7 analysts maintaining Strong Buy ratings despite the recent string of misses. The consensus price target of $12.67 implies 133% upside from current levels, suggesting the Street believes current challenges are temporary setbacks rather than fundamental flaws in the company's long-term value proposition.

Part 2: Historical Earnings Performance

Relmada's recent earnings history reveals a troubling pattern of consistent disappointments. Over the past four quarters, the company has missed analyst estimates in every single report, with surprises ranging from -20.00% to -650.00%.

The magnitude of these misses has been particularly severe. In Q3 2025 (September), RLMD posted a loss of $-0.30 versus expectations of just $-0.04, representing a staggering -650.00% miss. The Q4 2025 report showed a $-0.27 loss against a $-0.14 estimate (-92.86% miss), while the most recent Q1 2026 results came in at $-0.22 versus $-0.18 expected (-22.22% miss). Even the "best" performance in this stretch—Q2 2025—still delivered a -20.00% shortfall.

This consistent underperformance suggests either overly optimistic analyst modeling, unexpected development costs, or operational challenges that management has struggled to communicate effectively. The improving trend in miss magnitude (from -650% to -22%) offers a glimmer of hope that the company may be stabilizing, but investors will need to see an actual beat—or at minimum, an in-line result—to restore confidence in management's ability to execute against guidance.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Relmada reports after market close, meaning Day 0 reflects anticipatory trading before results are known, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price action around Relmada's earnings reveals moderate volatility with asymmetric risk. On average, the stock moves 1.90% on earnings day itself (Day 0) with an intraday range of 8.23%, while the following session (Day +1) sees larger directional moves averaging 4.97% with ranges expanding to 14.45%.

The most dramatic reaction came after the August 2024 report, when RLMD plunged 29.01% the day after results, demonstrating the downside risk when a clinical-stage biotech disappoints. More recently, volatility has moderated significantly—the May 2026 report produced only a 1.22% Day 0 move and 0.54% Day +1 move, suggesting the market may have already priced in lower expectations. However, the March 2026 report still generated a 13.01% Day +1 range, indicating that surprises can still trigger substantial price swings. Investors should prepare for potential double-digit percentage moves in either direction depending on whether the company can finally meet or beat estimates.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 13.59% (±$0.74) for the August 21 expiration, which aligns closely with the 14.45% average Day +1 range from historical earnings. This suggests options traders are anticipating typical volatility rather than an outsized reaction, though the elevated 92.21% implied volatility reflects the inherent uncertainty around clinical-stage biotech results.

Part 3: What Analysts Are Saying

Analyst sentiment on Relmada remains strongly bullish despite recent execution challenges. The consensus recommendation stands at 4.71 out of 5.0, with 6 Strong Buy ratings, 0 Moderate Buys, 1 Hold, and no Sell ratings among the 7 analysts covering the stock. This overwhelmingly positive stance suggests the Street views current operational struggles as temporary hurdles rather than fundamental problems with the company's long-term thesis.

The average price target of $12.67 implies substantial 133% upside from the current price of $5.44, with estimates ranging from a low of $9.00 to a high of $19.00. This wide range reflects differing views on the probability and timeline of successful clinical outcomes, but even the most conservative target suggests meaningful appreciation potential.

Analyst sentiment has remained unchanged over the past month, indicating the recent string of earnings misses hasn't prompted downgrades or target reductions. This stability suggests analysts are looking through near-term noise and maintaining conviction in the pipeline's value, though it also raises questions about whether the Street is adequately accounting for execution risk. The consensus appears to be betting that successful clinical milestones will ultimately overshadow the current pattern of disappointing quarterly results.

Part 4: Technical Picture

Relmada's technical setup heading into earnings shows deteriorating momentum after a strong year-to-date performance. The Barchart Technical Opinion currently registers a 24% Sell signal, down from 40% Buy just one month ago, reflecting recent weakness that has erased some of the stock's earlier gains.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative as the stock pulls back from recent highs
• Medium-term (Hold): Neutral reading suggests the intermediate trend remains in balance despite short-term weakness
• Long-term (Hold): Neutral signal reflects the stock's consolidation within a broader range over extended timeframes

Trend Characteristics: The trend is characterized as Weak and Weakening, suggesting momentum is fragile and vulnerable to further deterioration if earnings disappoint.

The moving average structure shows mixed signals. RLMD trades at $5.44, positioned above its 5-day ($5.37), 10-day ($5.28), and 200-day ($5.27) moving averages, but below the critical 20-day ($5.53), 50-day ($6.16), and 100-day ($6.58) levels. This configuration indicates the stock is caught in a downtrend from its recent peaks, with the 20-day average now acting as near-term resistance.

The 50-day moving average at $6.16 represents a key technical hurdle 12% above current levels, while support appears at the 200-day average of $5.27, just 3% below the current price. The stock's position in the lower half of its recent range, combined with weakening technical signals, suggests limited cushion for disappointment. However, the proximity to 200-day support could provide a floor if results meet expectations. Given the weak and weakening trend characteristics, the technical setup is cautionary heading into earnings—a beat could spark a relief rally back toward the 50-day average, while another miss risks a breakdown below long-term support.